Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Breast Cancer Liquid Biopsy Market Size Changed, over the years?
Recent years have seen a swift expansion in the size of the breast cancer liquid biopsy market. Projected growth from $0.78 billion in 2024 to $0.90 billion in 2025, indicates a compound annual growth rate (CAGR) of 15.0%. Factors contributing to this historic period of growth include the progression in next-generation sequencing (ngs), a surge in the prevalence of breast cancer, an escalating demand for non-invasive diagnostic procedures, the increased adoption of personalized medicine and a rise in funding for cancer research.
How Much Will the Breast Cancer Liquid Biopsy Market Be Worth in 2029?
In the coming years, the market size for liquid biopsies for breast cancer is set to experience a significant surge. It’s projected to reach a value of $1.56 billion by 2029 representing a 14.7% compound annual growth rate (CAGR). The projected growth for the forecast period can be attributed to technological evolution in liquid biopsy tests, increased use of these tests in preliminary cancer screening, a growing need for constant cancer monitoring, an expansion in its use in precision oncology, and increasing investments in liquid biopsy R&D. The forecast period will also witness major trends such as the integration of AI in liquid biopsy assessment, progress in single-cell sequencing, the development of multi-omics liquid biopsy platforms, enhancements in the sensitivity and specificity of liquid biopsy, and the adoption of digital PCR for ultra-accurate mutation detection.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21119&type=smp
Which is the Largest Company in the Breast Cancer Liquid Biopsy Market?
Major companies operating in the breast cancer liquid biopsy market are Johnson & Johnson Private Limited, Roche Diagnostics, Merck KGaA, Thermo Fisher Scientific, Siemens Healthineers, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc., RainDance Technologies, Biocept Inc., Fluxion Biosciences Inc., Angle plc
What Are the Main Market Drivers in the Breast Cancer Liquid Biopsy Industry?
Anticipated growth in the breast cancer liquid biopsy market is due to the rise in breast cancer cases. A form of cancer that originates in the cells of the breast, specifically within the lobules or milk-producing glands or ducts which transport milk to the nipple, is known as breast cancer. Influencing factors for an increase in breast cancer cases include a genetic inclination, hormonal inconsistencies, the aging population, changes in lifestyle, obesity, alcohol intake, lack of exercise, radiation exposure, and environmental pollutants. Breast cancer liquid biopsy aids the treatment process by detecting circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) present in the blood, thus providing real-time monitoring of the disease. Moreover, it assists in evaluating the treatment’s effectiveness, discerning resistance to therapy, and distinguishing genetic mutations that can be targeted for treatment. For example, the American Cancer Society, a nonprofit organization in the US that is dedicated to conducting cancer research, education, advocacy, and patient support, has predicted that there will be 319,750 new breast cancer cases in 2025 compared to 313,510 in 2024. Consequently, the rise in breast cancer cases is fuelling the growth of the breast cancer liquid biopsy market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21119&type=smp
How Is the Breast Cancer Liquid Biopsy Market Segments Structured?
The breast cancer liquid biopsy market covered in this report is segmented –
1) By Product: Consumables, Kits
2) By Biomarkers: Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor RNA (ctRNA), Circulating Tumor Cells (CTCs), Cell-free RNA (cfRNA), Other Biomarkers
3) By Application: Early Detection Or Screening, Diagnosis, Other Applications
4) By End Users: Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories
Subsegments:
1) By Consumables: Reagents, Polymerase Chain Reaction (PCR) Assays, Sequencing Panels, Sample Collection Tubes
2) By Kits: DNA-based Liquid Biopsy Kits, RNA-based Liquid Biopsy Kits, Multi-marker Liquid Biopsy Kits
What Strategic Trends Are Transforming the Breast Cancer Liquid Biopsy Market?
Key businesses in the breast cancer liquid biopsy market are concentrating on the advancement of innovative products, including companion diagnostics. These are designed to support personalized treatment strategies by recognizing patients who may profit from specific therapies. Companion diagnostics employ liquid biopsy methods to identify biomarkers such as genetic disruptions, circulating tumor DNA (ctDNA), or protein manifestations suggestive of a response to treatment. For example, in January 2023, Guardant Health Inc., a biotech firm based in the U.S., obtained approval from the Food and Drug Administration (FDA) for its Guardant360 CDx liquid biopsy examination to be used as a companion diagnostic for Menarini Group’s ORSERDU (elacestrant). This is a remedy for advanced or metastatic breast cancer sufferers who possess ESR1 mutations. This approval allows oncologists to utilise the test for thorough genomic profiling to identify patients likely to benefit from targeted therapy. This represents the first FDA approval for Guardant Health in the field of breast cancer, enhancing its role in precision oncology.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/breast-cancer-liquid-biopsy-global-market-report
Which Global Regions Offer the Highest Growth in the Breast Cancer Liquid Biopsy Market?
North America was the largest region in the breast cancer liquid biopsy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer liquid biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21119
This Report Delivers Insight On:
1. How big is the breast cancer liquid biopsy market, and how is it changing globally?
2. Who are the major companies in the breast cancer liquid biopsy market, and how are they performing?
3. What are the key opportunities and risks in the breast cancer liquid biopsy market right now?
4. Which products or customer segments are growing the most in the breast cancer liquid biopsy market?
5. What factors are helping or slowing down the growth of the breast cancer liquid biopsy market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model